Thermo Cardiosystems says HeartMate sales set for record:
This article was originally published in Clinica
Executive Summary
Thermo Cardiosystems is predicting a buoyant fourth quarter with sales up more than 15% over the previous quarter to $17 million. Its HeartMate left ventricular assist system (LVAS) sales have risen over 35% in the same period, to $7 million. The HeartMate is the only LVAS system approved in the US. Thermo Cardiosystems, which is a subsidiary of Thermo Electron, reports its full year figures in February.